JOIN MAILING LIST

PRESENTATION

PIPELINE

INVESTORS

ABOUT US

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed an innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, has the potential to better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles.

Oramed’s oral insulin is currently in advanced clinical trials under the US FDA for both type 1 and type 2 diabetes.

In addition to oral insulin, the company’s proprietary POD™ technology can be used to orally administer a number of protein-based therapies, which are available only via injection.

PRESS RELEASES

Sinopharm Capital-Hefei Signs Letter of Intent with Oramed for $50,000,000 Investment and Licensing Deal in China

July 7th, 2015|

JERUSALEM, July 7, 2015

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage […]

Oramed Enrolls First Patient in its Phase IIb Oral Insulin Study

June 30th, 2015|

Company’s largest study to date with over 30 clinical sites in […]